Guidance Point Advisors’s AstraZeneca AZN Stock Holding History

Guidance Point Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-599	Closed	-$71K	–	114
2021 Q3	$71K	Buy	+599	New	+$69.7K	0.03%	133

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Guidance Point Advisors's AZN Position: Q4 2021 in Review

Guidance Point Advisors sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 599 shares — an estimated $71K sold.

Guidance Point Advisors first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $71K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

Guidance Point Advisors reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
Guidance Point Advisors sold 599 AstraZeneca shares in Q4 2021, an estimated $71K.
Guidance Point Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
Guidance Point Advisors's AstraZeneca position peaked at $71K in Q3 2021.
949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Guidance Point Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.